Quarterly Activity Report and Appendix 4C – March 2021
>
>
Quarterly Activity Report and Appendix 4C – March 2021

Quarterly Activity Report and Appendix 4C – March 2021

Read the full Quarterly Activity Report and Appendix 4C ASX announcement HERE

ACTIVITIES REPORT FOR THE QUARTER ENDED 31 MARCH 2021

Corporate and Business updates for the Quarter

  • Progressive discussions and negotiations with potential OEMs including in the IVF market, Cell Therapy and target Biobanking space with interest for the Company’s products;
  • Agreed non-binding OEM term sheet following excellent progress made with a new potential OEM partner in the United States (USA);
  • Further development of Bluechiip direct to market portfolio of products for the Biobanking market including a range of Bluechiip Enabled and Bluechiip-branded range of cryogenic consumables with off-tool samples received;
  • Commenced the optimisation stage of the chip commercial production;
  • Successfully achieved the granting of a new patent – Sample Storage and Monitoring System – European Patent Grant EP2509412;
  • Cash receipts of $1.626m from the approved Australian Government’s Research and Development (R&D) Tax Incentive 2019/2020 rebate;
  • The Company is financially well supported with closing cash and cash equivalents of $5.97m as at 31 March 2021, with no borrowings;
  • The private mediation between the Company and Labcon North Americais well progressed towards an expected resolution via legal counsel in the USA with regard to the lawsuit filed against Labcon; and
  • Installation into end customer trial sites in North America and Australia.

Read the full Quarterly Activity Report and Appendix 4C ASX announcement HERE

Start typing and press Enter to search

Shopping Cart